Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet’s Disease
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Data Collection
2.2. Statistical Analysis
2.3. Ethical Approval
3. Results
3.1. General Characteristics of the Cohort
3.2. Sensitivity in Overall and Severe BD
3.3. Concordance Between ISG and ICBD for BD
3.4. Clinical Impact: Relationship with Biological Therapy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Yang, P.; Fang, W.; Meng, Q.; Ren, Y.; Xing, L.; Kijlstra, A. Clinical features of Chinese patients with Behçet’s disease. Ophthalmology 2008, 115, 312–318. [Google Scholar] [CrossRef]
- Suárez-Amorín, G.; Demetrio-Pablo, R.; Fernández-Ramón, R.; Herrero-Morant, A.; Álvarez-Reguera, C.; Sánchez-Bilbao, L.; Martínez-López, D.; Martín-Varillas, J.L.; Castañeda, S.; González-Gay, M.A.; et al. Epidemiology and clinical domains of Behçet’s disease in the Cantabria region, Northern Spain. Clin. Exp. Rheumatol. 2023, 41, 1991–1997. [Google Scholar] [CrossRef]
- Calamia, K.T.; Wilson, F.C.; Icen, M.; Crowson, C.y.S.; Gabriel, S.E.; Kremers, H.M. Epidemiology and clinical characteristics of behcet’s disease in the us: A population-based study. Arthritis Care Res. 2009, 61, 600–604. [Google Scholar] [CrossRef] [PubMed]
- Zouboulis, C.C.; Kotter, I.; Djawari, D.; Kirch, W.; Kohl, P.K.; Ochsendorf, F.R.; Keitel, W.; Stadler, R.; Wollina, U.; Proksch, E.; et al. Epidemiological features of Adamantiades-BehÇet’s disease in Germany and in Europe. Yonsei Med. J. 1997, 38, 411. [Google Scholar] [CrossRef] [PubMed]
- Davatchi, F.; Chams-Davatchi, C.; Shams, H.; Shahram, F.; Nadji, A.; Akhlaghi, M.; Faezi, T.; Ghodsi, Z.; Abdollahi, B.S.; Ashofteh, F.; et al. Behcet’s disease: Epidemiology, clinical manifestations, and diagnosis. Expert Rev. Clin. Immunol. 2017, 13, 57–65. [Google Scholar] [CrossRef] [PubMed]
- Emmi, G.; Bettiol, A.; Hatemi, G.; Prisco, D. Behçet’s syndrome. Lancet 2024, 403, 1093–1108. [Google Scholar] [CrossRef]
- Attia, D.H.S.; Abdel Noor, R.A. Severe Behçet’s disease equally affects both genders in Egyptian patients: A multicentre retrospective follow-up study. Reumatismo 2020, 71, 218–225. [Google Scholar] [CrossRef]
- Ozguler, Y.; Merkel, P.A.; Gurcan, M.; Bocage, C.; Eriksen, W.; Kutlubay, Z.; Hatemi, G.; Cronholm, P.F. Patients’ experiences with Behçet’s syndrome: Structured interviews among patients with different types of organ involvement. Clin. Exp. Rheumatol. 2019, 37 (Suppl. S121), 28–34. [Google Scholar] [PubMed]
- Criteria for Diagnosis of Behçet’s Disease. International Study Group for Behçet’s Disease. Lancet 1990, 335, 1078–1080. [Google Scholar] [CrossRef]
- Davatchi, F.; Assaad-Khalil, S.; Calamia, K.T.; Crook, J.E.; Sadeghi-Abdollahi, B.; Schirmer, M.; Tzellos, T.; Zouboulis, C.C.; Akhlagi, M.; Al-Dalaan, A.; et al. The International Criteria for Behçet’s Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J. Eur. Acad. Dermatol. Venereol. 2014, 28, 338–347. [Google Scholar] [CrossRef]
- Barroso-García, N.; Atienza-Mateo, B.; Ferraz-Amaro, I.; Prieto-Peña, D.; Beltrán, E.; Adán, A.; Hernández-Garfella, M.; Martínez-Costa, L.; Cordero-Coma, M.; Díaz-Llopis, M.; et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet’s disease. Multicenter study of 49 patients. Semin. Arthritis Rheum. 2023, 58, 152–153. [Google Scholar] [CrossRef]
- Atienza-Mateo, B.; Martín-Varillas, J.L.; Graña, J.; Espinosa, G.; Moriano, C.; Pérez-Sandoval, T.; Martín-Martínez, M.; Díez-Álvarez, E.; García-Armario, M.D.; Martínez, E.; et al. Apremilast in refractory orogenital ulcers and other manifestations of Behçet’s disease. A national multicentre study of 51 cases in clinical practice. Clin. Exp. Rheumatol. 2020, 38 (Suppl. S127), S69–S75. [Google Scholar] [PubMed]
- Atienza-Mateo, B.; Beltrán, E.; Hernández-Garfella, M.; Pascual, E.V.; Martínez-Costa, L.; Atanes, A.; Moriano, C.; Cordero-Coma, M.; Nolla, J.M.; Cubero, C.C.; et al. Tocilizumab in Behçet’s disease with refractory ocular and/or neurological involvement: Response according to different clinical phenotypes. Clin. Exp. Rheumatol. 2021, 39, 37–42. [Google Scholar] [CrossRef]
- Zhong, Z.; Liao, W.; Gao, Y.; Su, G.; Feng, X.; Yang, P. Evaluation of sensitivity and specificity of diagnostic criteria for Behçet’s disease in the absence of a gold standard. Rheumatology 2022, 61, 3667–3676. [Google Scholar] [CrossRef]
- Leeflang, M.M.G.; Rutjes, A.W.S.; Reitsma, J.B.; Hooft, L.; Bossuyt, P.M.M. Variation of a test’s sensitivity and specificity with disease prevalence. Can. Med. Assoc. J. 2013, 185, E537–E544. [Google Scholar] [CrossRef]
- Leeflang, M.M.G.; Bossuyt, P.M.M.; Irwig, L. Diagnostic test accuracy may vary with prevalence: Implications for evidence-based diagnosis. J. Clin. Epidemiol. 2009, 62, 5–12. [Google Scholar] [CrossRef]
- Landis, J.R.; Koch, G.G. The Measurement of Observer Agreement for Categorical Data. Biometrics 1977, 33, 159–174. [Google Scholar] [CrossRef]
- Alibaz-Oner, F.; Direskeneli, H. Update on the Diagnosis of Behçet’s Disease. Diagnostics 2023, 13, 41. [Google Scholar] [CrossRef]
- Kiafar, M.; Faezi, S.T.; Kasaeian, A.; Baghdadi, A.; Kakaei, S.; Mousavi, S.A.; Nejadhosseinian, M.; Shahram, F.; Ghodsi, S.Z.; Shams, H.; et al. Diagnosis of Behçet’s disease: Clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol. 2021, 5, 2. [Google Scholar] [CrossRef]
- Ortiz-Fernández, L.; Sawalha, A.H. Genetics of Behçet’s Disease: Functional Genetic Analysis and Estimating Disease Heritability. Front. Med. 2021, 8, 680124. [Google Scholar] [CrossRef]
- Saadoun, D.; Wechsler, B. Behçet’s disease. Orphanet J. Rare Dis. 2012, 7, 20. [Google Scholar] [CrossRef] [PubMed]
Expert Diagnosis (N = 142) | ISG Criteria (N = 84) | ICBD Criteria (N = 116) | ISG vs. ICBD p Value | |
---|---|---|---|---|
Demographic data | ||||
Age, mean (SD) | 36.4 (13.9) | 35 (12.8) | 37 (13.2) | |
Gender, n (%) | ||||
Male | 73 (51.4) | 41 (48.8) | 57 (49.1) | 0.80 |
Female | 69 (48.6) | 43 (51.2) | 59 (50.9) | 0.59 |
Clinical manifestations n (%) | ||||
Oral aphthosis | 135 (95.1) | 84 (100) | 115 (99.1) | 0.99 |
Recurrent (≥3 times/year) | 115 (81) | 72 (85.7) | 102 (87.9) | 0.80 |
Genital aphthosis | 88 (62) | 67 (79.7) | 88 (75.8) | 0.63 |
Skin manifestations | 91 (64.1) | 74 (88.1) | 79 (68.1) | 0.01 |
Ocular involvement | 60 (42.3) | 49 (58.3) | 55 (47.4) | 0.13 |
Uveitis | 52 (36.6) | 42 (50) | 47 (40.5) | 0.18 |
Anterior | 20 (14.1) | 20 (23.8) | 20 (17.2) | 0.25 |
Intermediate | 3 (2.1) | 0 | 2 (1.7) | 0.51 |
Posterior | 14 (9.9) | 11 (13.1) | 13 (11.2) | 0.68 |
Panuveitis | 14 (9.9) | 10 (11.9) | 11 (9.5) | 0.58 |
Unilateral | 29 (20.4) | 25 (29.8) | 28 (24.1) | 0.37 |
Bilateral | 23 (16.2) | 17 (20.2) | 19 (16.4) | 0.49 |
Dry eye | 8 (5.6) | 7 (8.3) | 8 (6.9) | 0.71 |
Scleritis | 0 | 0 | 0 | 0.99 |
Episcleritis | 4 (2.8) | 3 (3.6) | 4 (3.4) | 0.99 |
PUK | 1 (0.7) | 1 (1.2) | 1 (0.86) | 0.90 |
Joint manifestations | 87 (61.3) | 52 (61.9) | 71 (61.2) | 0.99 |
Neurological manifestations | 29 (20.4) | 13 (15.4) | 22 (18.9) | 0.65 |
Vascular manifestations | 19 (13.4) | 9 (10.7) | 17 (14.6) | 0.54 |
Complementary tests n (%) | ||||
Pathergy positive test | 7 (5) | 6 (7.1) | 6 (5.1) | 0.78 |
HLA 51 positive | 51 (36) | 25 (29.7) | 38 (32.7) | 0.76 |
Treatment, n (%) | ||||
Anti-TNF treatment | 36 (25.3) | 28 (33.3) | 35 (30.1) | 0.63 |
Infliximab | 15 (10.5) | 12 (14.2) | 15 (12.9) | 0.78 |
Adalimumab | 20 (14.1) | 15 (17.8) | 19 (16.3) | 0.78 |
Etanercept | 1 (0.7) | 1 (1.2) | 1 (0.8) | 0.99 |
Apremilast | 10 (7) | 7 (8.3) | 9 (7.7) | 0.88 |
Anti-IL6r (Tozilizumab) | 1 (0.7) | 0 | 0 | 0.99 |
ISG | ICBD | |
---|---|---|
Sensitivity (%) | 59.1 | 81.6 |
Sensitivity in severe cases (%) | 71.2 | 92.5 |
Positive specific agreement (%) | 84.0 (78.3–88.4) | |
Negative specific agreement (%) | 61.9 (51.2–71.6) | |
Overall agreement (%) | 77.5 (69.9–83.6) | |
Kappa (95% CI) | 0.490 (0.356–0.623) | |
PABAK | 0.549 |
Condition | Kappa (Added) | PABAK (Added) | Kappa (Removed) | PABAK (Removed) |
---|---|---|---|---|
Ocular | 0.405 (0.176–0.634) | 0.788 | 0.443 (0.326–0.561) | 0.408 |
Vascular | 0.216 (0.103–0.330) | 0.338 | 0.559 (0.427–0.690) | 0.605 |
Neurological | 0.235 (0.118–0.353) | 0.352 | 0.507 (0.374–0.640) | 0.563 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gálvez-Sánchez, R.; Martín-Varillas, J.L.; Sánchez-Bilbao, L.; Ferraz-Amaro, I.; Aurrecoechea, E.; Prieto-Peña, D.; Blanco, R. Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet’s Disease. J. Clin. Med. 2025, 14, 5559. https://doi.org/10.3390/jcm14155559
Gálvez-Sánchez R, Martín-Varillas JL, Sánchez-Bilbao L, Ferraz-Amaro I, Aurrecoechea E, Prieto-Peña D, Blanco R. Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet’s Disease. Journal of Clinical Medicine. 2025; 14(15):5559. https://doi.org/10.3390/jcm14155559
Chicago/Turabian StyleGálvez-Sánchez, Rafael, José Luis Martín-Varillas, Lara Sánchez-Bilbao, Iván Ferraz-Amaro, Elena Aurrecoechea, Diana Prieto-Peña, and Ricardo Blanco. 2025. "Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet’s Disease" Journal of Clinical Medicine 14, no. 15: 5559. https://doi.org/10.3390/jcm14155559
APA StyleGálvez-Sánchez, R., Martín-Varillas, J. L., Sánchez-Bilbao, L., Ferraz-Amaro, I., Aurrecoechea, E., Prieto-Peña, D., & Blanco, R. (2025). Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet’s Disease. Journal of Clinical Medicine, 14(15), 5559. https://doi.org/10.3390/jcm14155559